Promising drug trodelvy tested as first defense against aggressive breast cancer
Disease control
Not yet recruiting
This phase 2 trial is testing the drug sacituzumab govitecan (Trodelvy) as a first treatment for people with advanced triple-negative breast cancer who haven't had prior therapy for advanced disease. Researchers want to see if the drug can shrink tumors or slow the cancer's growt…
Phase: PHASE2 • Sponsor: Nathalie Levasseur • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC